622 related articles for article (PubMed ID: 26843468)
41. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.
Lethagen S; Kyrle PA; Castaman G; Haertel S; Mannucci PM;
J Thromb Haemost; 2007 Jul; 5(7):1420-30. PubMed ID: 17439628
[TBL] [Abstract][Full Text] [Related]
42. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
Batty P; Chen YH; Bowles L; Hart DP; Platton S; Pasi KJ
Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness and safety of hFVIII/VWF concentrate (Voncento
Rugeri L; d'Oiron R; Harroche A; Proulle V; Mourey G; De Raucourt E; Desprez D; Baikian NI; Petesch BP; Borel-Derlon A; Combe S; Frotscher B; Hassoun A; Catovic H; Bracquart D; Trossaërt M
Blood Transfus; 2021 Mar; 19(2):152-157. PubMed ID: 33263522
[TBL] [Abstract][Full Text] [Related]
44. Laboratory diagnostic approach of the parents-children relationship in differentiating low-level von Willebrand factor from mild type 1 von Willebrand disease.
Akin M
Blood Coagul Fibrinolysis; 2012 Jun; 23(4):351-3. PubMed ID: 22450546
[TBL] [Abstract][Full Text] [Related]
45. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
46. Biological effects of a S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease.
Meriane F; Zerhouni L; Djeha N; Goudemand M; Mazurier C
Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1023-9. PubMed ID: 8148475
[TBL] [Abstract][Full Text] [Related]
47. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
48. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
[TBL] [Abstract][Full Text] [Related]
49. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
50. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
Castaman G; Tosetto A; Federici AB; Rodeghiero F
Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
[TBL] [Abstract][Full Text] [Related]
51. Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a Tertiary Care Center.
Moonla C; Akkawat B; Kittikalayawong Y; Sukperm A; Meesanun M; Uaprasert N; Sosothikul D; Rojnuckarin P
Clin Appl Thromb Hemost; 2019; 25():1076029619866916. PubMed ID: 31359769
[TBL] [Abstract][Full Text] [Related]
52. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
53. The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease.
Stakiw J; Bowman M; Hegadorn C; Pruss C; Notley C; Groot E; Lenting PJ; Rapson D; Lillicrap D; James P
J Thromb Haemost; 2008 Jan; 6(1):90-6. PubMed ID: 17922807
[TBL] [Abstract][Full Text] [Related]
54. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients.
Federici AB; Castaman G; Franchini M; Morfini M; Zanon E; Coppola A; Tagliaferri A; Boeri E; Mazzucconi MG; Rossetti G; Mannucci PM
Haematologica; 2007 Jul; 92(7):944-51. PubMed ID: 17606445
[TBL] [Abstract][Full Text] [Related]
55. Are Iranian patients with von Willebrand disease type 2N properly differentiated from hemophilia A and do they receive appropriate treatment?
Seidi Zadeh O; Ahmadinejad M; Amoohossein B; Homayoun S
Blood Coagul Fibrinolysis; 2020 Sep; 31(6):382-386. PubMed ID: 32815913
[TBL] [Abstract][Full Text] [Related]
56. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study.
Pagliari MT; Rosendaal FR; Ahmadinejad M; Badiee Z; Baghaipour MR; Baronciani L; Benítez Hidalgo O; Bodó I; Budde U; Castaman G; Eshghi P; Goudemand J; Karimi M; Keikhaei B; Lassila R; Leebeek FWG; Lopez Fernandez MF; Mannucci PM; Marino R; Oldenburg J; Peake I; Santoro C; Schneppenheim R; Tiede A; Toogeh G; Tosetto A; Trossaert M; Yadegari H; Zetterberg EMK; Peyvandi F; Federici AB; Eikenboom J
J Thromb Haemost; 2022 May; 20(5):1106-1114. PubMed ID: 35092343
[TBL] [Abstract][Full Text] [Related]
57. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
[TBL] [Abstract][Full Text] [Related]
58. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD).
Tosetto A; Rodeghiero F; Castaman G; Bernardi M; Bertoncello K; Goodeve A; Federici AB; Batlle J; Meyer D; Mazurier C; Goudemand J; Eikenboom J; Schneppenheim R; Budde U; Ingerslev J; Vorlova Z; Habart D; Holmberg L; Lethagen S; Pasi J; Hill F; Peake I
J Thromb Haemost; 2007 Apr; 5(4):715-21. PubMed ID: 17408405
[TBL] [Abstract][Full Text] [Related]
59. von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.
Atiq F; Schütte LM; Looijen AEM; Boender J; Cnossen MH; Eikenboom J; de Maat MPM; Kruip MJHA; Leebeek FWG
Blood Adv; 2019 Dec; 3(24):4147-4154. PubMed ID: 31834934
[TBL] [Abstract][Full Text] [Related]
60. Treatment of von Willebrand Disease.
Curnow J; Pasalic L; Favaloro EJ
Semin Thromb Hemost; 2016 Mar; 42(2):133-46. PubMed ID: 26838696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
